Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 28
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Zhonghua Yu Fang Yi Xue Za Zhi ; 57(8): 1147-1152, 2023 Aug 06.
Artículo en Zh | MEDLINE | ID: mdl-37574304

RESUMEN

Objective: To investigate the association between chronic lung diseases and the risk of lung cancer. Methods: Using UK Biobank (UKB) survey data, 472 397 participants who had not previously been diagnosed with cancer and whose self-reported sex was consistent with their genetic sex were studied. Information on the prevalence of previous chronic lung diseases, general demographic characteristics and the prevalence of lung cancer was collected using baseline questionnaires and national health system data. The multivariate Cox proportional risk regression model was used to analyze the association between four previous chronic lung diseases (asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and interstitial pulmonary disease) and the risk of lung cancer. A total of 458 526 participants with genotype data in the observational study were selected as research objects, and the closely related and independent genetic loci with four chronic lung diseases were selected as instrumental variables, and the association between four chronic lung diseases and the risk of lung cancer was analyzed by Mendelian randomization (MR). The dose-response relationship between genetic risk score and the risk of lung cancer in different chronic lung diseases was evaluated using a restricted cubic spline function. Results: The age [M (Q1, Q3)] of the subjects was 57 (50, 63) years old, and there were 3 516 new cases of lung cancer (0.74%) during follow-up. The multivariate Cox proportional hazard regression model analysis showed that previous chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis were associated with the risk of lung cancer, about 1.61 (1.49-1.75) and 2.61 (1.24-5.49), respectively. MR Studies showed that genetically predicted chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis were associated with the risk of lung cancer, with HR (95%CI) of 1.10 (1.03-1.19) and 1.04 (1.01-1.08), respectively. The results of restricted cubic spline function analysis showed that the risk of lung cancer increased linearly with the increase of genetic risk scores for chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis (P<0.05). Neither observational studies nor Mendelian randomization analysis found an association between previous asthma or interstitial lung disease and the risk of lung cancer (both P values>0.05). Conclusion: Chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis are potential risk factors for lung cancer.


Asunto(s)
Asma , Fibrosis Pulmonar Idiopática , Neoplasias Pulmonares , Enfermedad Pulmonar Obstructiva Crónica , Humanos , Persona de Mediana Edad , Análisis de la Aleatorización Mendeliana , Bancos de Muestras Biológicas , Neoplasias Pulmonares/epidemiología , Neoplasias Pulmonares/genética , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Enfermedad Pulmonar Obstructiva Crónica/genética , Asma/epidemiología , Asma/genética , Fibrosis Pulmonar Idiopática/epidemiología , Fibrosis Pulmonar Idiopática/genética , Reino Unido/epidemiología , Estudio de Asociación del Genoma Completo
2.
Zhonghua Liu Xing Bing Xue Za Zhi ; 43(12): 1875-1880, 2022 Dec 10.
Artículo en Zh | MEDLINE | ID: mdl-36572457

RESUMEN

Objective: To evaluate the possible mediation effect of smoking and healthy diet score on the association between educational level and the risk of lung cancer incidence. Methods: After excluding individuals with missing educational levels and cancer information at baseline, 446 772 participants in the UK Biobank (UKB) prospective cohort study were included. Cox regression models were used to investigate the associations of educational level and smoking and healthy diet score with the incidence of lung cancer. Mediating effect analysis was conducted to analyze the mediating effect of smoking and healthy diet score on the correlation between educational level and lung cancer. Results: During a median follow-up of 7.13 years, 1 994 new- onset lung cancer cases were observed. Per 1 standard deviation (5 years) increase in educational level was associated with a 12% lower risk of lung cancer (HR=0.88, 95%CI: 0.84-0.92). The corresponding level 1-5 in the International Standard Classification for Education (ISCED) were mapped to UKB self-report highest qualification to estimate the educational level. A higher rank means a higher educational level. Compared with level ISCED-1, the HR(95%CI) of level ISCED-2, ISCED-3, ISCED-4 and ISCED-5 were respectively 0.83 (0.72-0.94), 0.67 (0.53-0.85), 0.76 (0.65-0.89) and 0.72 (0.64-0.80) for lung cancer. Education years were negatively correlated with smoking, with ß coefficients (95%CI) being -0.079 (-0.081- -0.077), but positively correlated with healthy diet score (ß=0.042, 95%CI: 0.039-0.045). Analysis of mediating effect indicated that the association of educational level with lung cancer risk was mediated by smoking and healthy diet score, the proportions of mediating effect were 38.952% (95%CI: 31.802%-51.659%) and 1.784% (95%CI: 0.405%-3.713%), respectively. Conclusion: Smoking and healthy diet score might mediate the effect of educational level on the incidence of lung cancer, indicating that improving the level of education can reduce the risk of lung cancer by changing lifestyles such as smoking and diet.


Asunto(s)
Neoplasias Pulmonares , Fumar , Humanos , Fumar/efectos adversos , Fumar/epidemiología , Factores de Riesgo , Dieta Saludable , Estudios Prospectivos , Incidencia , Neoplasias Pulmonares/epidemiología , Dieta , Escolaridad
3.
J Mycol Med ; 28(1): 36-44, 2018 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-29477784

RESUMEN

OBJECTIVE: The aim of this study was to investigate the antifungal activity of dracorhodin perchlorate (DP) against planktonic growth and virulence factors of Candida albicans. METHODS: Microdilution method based on CLSI-M27-A3 was used to test the antifungal susceptibility of DP. The activity of DP against biofilm formation and development of C. albicans was quantified by XTT assay and visualized by confocal laser scanning microscope. The effect of DP on the morphological transition of C. albicans induced by four kinds of hyphal-inducing media at 37°C for 4hours was observed under microscope. The rescue experiment by adding exogenous cAMP analog was performed to investigate the involvement of cAMP in the yeast to hyphal transition and biofilm formation of C. albicans. Egg yolk emulsion agar was used to determine the inhibition of DP on the phospholipase production of C. albicans. Human JEG-3 and HUVEC cell lines, as well as the nematode Caenorhabditis elegans was used to assess the toxicity of DP. RESULTS: The minimum inhibitory concentration (MIC) of DP is 64µM while the antifungal activity was fungistatic. As low as a concentration at 16µM, DP could inhibit the yeast to hyphal transition in liquid RPMI-1640, Spider, GlcNAc and 10% FBS-containing Sabouroud Dextrose medium, as well as on the solid spider agar. Exogenous cAMP analog could rescue part of biofilm viability of C. albicans. DP could inhibit the production of phospholipase. The toxicity of DP against human cells and C. elegans is low. CONCLUSION: DP could inhibit the planktonic growth and virulent factors in multiple stages, such as yeast to hyphal transition, adhesion, biofilm formation and production of phospholipase of C. albicans.


Asunto(s)
Antifúngicos/farmacología , Benzopiranos/farmacología , Biopelículas/efectos de los fármacos , Candida albicans/efectos de los fármacos , Hifa/efectos de los fármacos , Animales , Antifúngicos/administración & dosificación , Antifúngicos/toxicidad , Benzopiranos/administración & dosificación , Benzopiranos/toxicidad , Caenorhabditis elegans/efectos de los fármacos , Candida albicans/enzimología , Candida albicans/crecimiento & desarrollo , Candida albicans/patogenicidad , Línea Celular Tumoral , Humanos , Pruebas de Sensibilidad Microbiana , Fosfolipasas/efectos de los fármacos , Virulencia/efectos de los fármacos , Factores de Virulencia
5.
Curr Drug Targets Infect Disord ; 3(3): 241-6, 2003 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-14529356

RESUMEN

Based on the recent studies of HBV strains with different replication efficiency, several new potential targets for anti-HBV replication have been presented. These include the viral and cellular regulatory factors associated with HBV replication and the process for encapsidation of viral genome and budding into endoplasmic reticulum (ER). A putative regulatory domain has been reported at the carboxyl-end of reverse transcriptase (RT) and when serine is substituted for proline at residue 652 of RT, replication efficiency of HBV is decreased. Substitution of proline for threonine at the 2798 nucleotide of the terminal protein (TP) gene, renders the mutant completely replication deficient. Expression of TP blocks the interferon (IFN) pathway and inhibits the responsive state of cells to interferons ( IFN) alpha and gamma. Interference of HBV capsid assembly drastically affects the encapsidation of viral genome, a crucial process for reverse transcription and viral DNA synthesis. Small molecules (bis-ANS) have been reported to act as a "wedge" to misdirect the polymerization of capsid, resulting in inhibition of virus replication. Another new group of compounds (HAP) has been shown to inhibit virus replication and also inhibit the assembly of viral capsid (core particle). Finally the capsids containing HBV genome are enveloped by budding into endoplasmic reticulum and release from virus infected cells, and this morphogenesis and secretion of HBV is dependent on glucosidases in the ER of host cells. Competitive inhibition of these glucosidases has been suggested as strategy against HBV replication.


Asunto(s)
Antivirales/farmacología , Virus de la Hepatitis B/efectos de los fármacos , Cápside/efectos de los fármacos , ADN Polimerasa Dirigida por ADN/química , ADN Polimerasa Dirigida por ADN/fisiología , Diseño de Fármacos , Productos del Gen pol/química , Productos del Gen pol/fisiología , Virus de la Hepatitis B/química , Humanos , ADN Polimerasa Dirigida por ARN/química , ADN Polimerasa Dirigida por ARN/fisiología , Proteínas del Envoltorio Viral/antagonistas & inhibidores , Proteínas del Envoltorio Viral/fisiología , Replicación Viral/efectos de los fármacos , Replicación Viral/genética
6.
Acta Virol ; 40(5-6): 311-4, 1996.
Artículo en Inglés | MEDLINE | ID: mdl-9171461

RESUMEN

The envelope (Pre-S/S) gene of duck hepatitis B virus (DHBV) was amplified by polymerase chain reaction (PCR) and cloned into plasmid pGJP5, under the control of vaccinia virus promoter P(7.5). By recombination in cell culture, and screened in human TK- 143 cells in the presence of 5-bromouracil deoxyriboside (5-BUdR), a recombinant vaccinia virus, bearing the envelope gene of DHBV (pGDHBV-5) which could replicate in cell cultures was constructed. DHBV surface antigen (DHBsAg) was detected in pGDHBV-5-infected cell lysate by dot enzyme immunoassay (EIA). After multiple-site intradermal injections of pGDHBV-5, DHBsAg could be detected in the serum of immunized adult ducks. This indicated that the recombinant virus replicated and expresed DHBsAg in ducks. The recombinant virus was used as a therapeutic vaccine to immunize persistently DHBV-infected ducks. After immunization, a transient significant decrease of serum DHBsAg was observed.


Asunto(s)
Vectores Genéticos , Infecciones por Hepadnaviridae/terapia , Vacunas contra Hepatitis B/uso terapéutico , Virus de la Hepatitis B del Pato/inmunología , Vacunas Sintéticas/uso terapéutico , Virus Vaccinia , Proteínas del Envoltorio Viral , Proteínas Virales/uso terapéutico , Animales , Chlorocebus aethiops , Patos , Expresión Génica , Virus de la Hepatitis B del Pato/genética , Virus de la Hepatitis B del Pato/fisiología , Humanos , Conejos , Recombinación Genética , Células Vero , Proteínas Virales/genética , Latencia del Virus
7.
Zhonghua Wai Ke Za Zhi ; 27(9): 528-30, 573-4, 1989 Sep.
Artículo en Zh | MEDLINE | ID: mdl-2560963

RESUMEN

DSA and venography were performed in 13 hepatic carcinomas of central type for the location of the tumor. The procedure was found to clearly show the mass in its relation to hepatic veins. Preoperative demonstration of the landmarks of the hepatic lobes and segments was helpful to accomplish hepatic lobectomy or segmentectomy. The authors elaborated the technic and points for attention involved in this modality. The value of the hepatic arteriography and Venography in clinical application is discussed and indications are put forward.


Asunto(s)
Angiografía de Substracción Digital , Carcinoma Hepatocelular/diagnóstico por imagen , Neoplasias Hepáticas/diagnóstico por imagen , Adulto , Arteria Hepática/diagnóstico por imagen , Venas Hepáticas/diagnóstico por imagen , Humanos , Masculino , Persona de Mediana Edad
8.
Zhonghua Wai Ke Za Zhi ; 32(1): 31-4, 1994 Jan.
Artículo en Zh | MEDLINE | ID: mdl-8045198

RESUMEN

From Sep. 1985 to Dec. 1990, surgical treatment was performed in 27 patients with small primary liver cancer (SPLC, < or = 5cm in diameter). Of them, segmentectomy was done in 23 cases and radical local resection in 4 cases with recurrence rate of 66.77% (18/27). Non recurrent lesions were located in the incisal margin. In this group re-resection rate was 55.6% (10/18). (1) Early detection and treatment of recurrent lesions remain a mainstay of prolonging survival. (2) Serum Alpha-fetoprotein (AFP), ultrasonography and X-ray chest film were basic follow-up methods for subclinical recurrence of SPLC. For re-operation cases, digital subtract angiography (DSA) are useful in identifying subclinical lesions. (3) For recurrent liver cancer local hepatectomy was a reasonable approach. (4) For SPLC, radical segmentectomy or radical local resection with a safe margin of 1 to 2cm was the authors' choice.


Asunto(s)
Carcinoma Hepatocelular/cirugía , Hepatectomía/métodos , Neoplasias Hepáticas/cirugía , Recurrencia Local de Neoplasia/prevención & control , Femenino , Humanos , Masculino , Persona de Mediana Edad , Reoperación
9.
Artículo en Zh | MEDLINE | ID: mdl-8168241

RESUMEN

This paper reports the experiments in which tripynadine free base at a dose 4.5 times that of ED50 was given to mice by intragastric administration. On the 20th day following the administration the mice were inoculated with 1 x 10(7) RBC infected with Plasmodium berghei ANKA strain. The infection rate was zero, implying that all mice had acquired protection. Although the residual activity time of tripynadine phosphate was longer than that of tripynadine free base or piperaquine phosphate, but tripynadine phosphate caused vomiting in monkeys during the medication. The residual antimalarial activity of tripynadine hydroxynaphthoate was less than that of tripynadine phosphate or tripynadine free base. A total dose of 200 mg/kg of tripynadine free base ensured residual antimalarial activity against P. cynomolgi bastianellii for 20 days. However, the residual activity decreased evidently when the total dose was reduced to 100 mg/kg. In short, it seems that the residual antimalarial activity of tripynadine free base is slightly less than that of piperaquine in monkeys.


Asunto(s)
Antimaláricos/uso terapéutico , Malaria/prevención & control , Naftiridinas/uso terapéutico , Plasmodium berghei , Plasmodium cynomolgi , Animales , Macaca mulatta , Ratones , Quinolinas/uso terapéutico
10.
Artículo en Zh | MEDLINE | ID: mdl-2680154

RESUMEN

Field trials were carried out to assess the therapeutic effects including the combined use of piperaquine (PQ) with nitroquine (NQ) and pyronaridine (PYR) with NQ against falciparum malaria in regions of Hainan Province with chloroquine-resistance in 3 successive autumns from 1985 to 1987. In an evaluation of PQ 750 mg with NQ 25 mg therapy in 33 falciparum malaria patients, the average fever subsidence time and parasite clearance time were 39 hours and 49 hours respectively, but within 28 days after medication, the recrudescence rates were 0-47% in different regions. In evaluations of PYR 600 mg with NQ 25 mg in 11 cases, PYR 800 mg with NQ 40 mg in 43 cases, PYR 800 mg with NQ 80 mg in 31 cases, the fever subsidence time were 31-35 hours, the parasite clearance time were 46-53 hours and the 28 days recrudescence rates were 13-18%. In the control, the use of PYR 1,200 mg alone in 42 cases, the average fever subsidence time and parasite clearance time were 33 hours and 48 hours respectively, the 28 days recrudescence rate was 12%. There was no statistically significant difference among them in their effects. The side-effects of all groups were mild.


Asunto(s)
Antimaláricos/uso terapéutico , Malaria/tratamiento farmacológico , Adolescente , Adulto , Animales , Quimioterapia Combinada , Femenino , Humanos , Masculino , Naftiridinas/administración & dosificación , Plasmodium falciparum , Quinazolinas/administración & dosificación , Quinolinas/administración & dosificación
11.
Eur J Surg Oncol ; 40(7): 869-74, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24613740

RESUMEN

BACKGROUND: This study was to evaluate the clinicopathological and prognostic features of follicular thyroid carcinoma (FTC) in our institute over a 15-year period. METHODS: The clinical features, management and outcome of 134 consecutive patients were analyzed according to the time of diagnosis: Group I (1997-2001), Group II (2002-2006), and Group III (2007-2011). RESULTS: As time advanced, the ratio of FTC to papillary thyroid carcinoma decreased from 8.7% in group I to 4.3% in group III (p = 0.000). The percentage of patients undergoing total thyroidectomy seemed to be more commonly used in the later periods - from 10.5% in group I to 21.8% in group II and 18.9% in group III. The median diameter of tumors in group I was 4.2 cm and it showed a sharp decrease to 2.8 cm in group II and 2.9 cm in group III respectively. There was a trend towards a higher stage in patients from Group I vs. patients from Groups II and III (stage IV, 15.8% vs. 2.2% and 4.3%, p = 0.072). The outcome was improved in terms of disease-free survival (DFS). The 3-year DFS rate improved from 77.8% in group I to 93.7% in group II and 100% in group III (p = 0.008). CONCLUSIONS: The clinical features, management and outcome of FTC patients changed over 15-year period. Patients diagnosed after 2001 had a better prognosis. This improvement was probably related to earlier diagnosis with smaller tumor size and presentation at earlier tumor stage.


Asunto(s)
Adenocarcinoma Folicular/mortalidad , Adenocarcinoma Folicular/patología , Ganglios Linfáticos/patología , Neoplasias de la Tiroides/mortalidad , Neoplasias de la Tiroides/patología , Adenocarcinoma Folicular/cirugía , Adolescente , Adulto , Anciano , Biopsia con Aguja , Distribución de Chi-Cuadrado , China , Estudios de Cohortes , Supervivencia sin Enfermedad , Femenino , Hospitales Universitarios , Humanos , Inmunohistoquímica , Estimación de Kaplan-Meier , Ganglios Linfáticos/cirugía , Masculino , Persona de Mediana Edad , Invasividad Neoplásica/patología , Estadificación de Neoplasias , Cuidados Posoperatorios/métodos , Pronóstico , Estudios Retrospectivos , Medición de Riesgo , Análisis de Supervivencia , Neoplasias de la Tiroides/cirugía , Tiroidectomía/métodos , Factores de Tiempo , Resultado del Tratamiento , Adulto Joven
19.
Mucosal Immunol ; 1(6): 497-507, 2008 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19079217

RESUMEN

Systemic immunization of macaques with a combination of DNA-poxvirus-based vaccines confers protection from high level of both systemic and mucosal viral replication following rectal exposure to the pathogenic SIV(mac251). Here we investigated early post-infection events in rectal and vaginal tissues, and found that the loss of CCR5+CD4+ T cells was equivalent in vaccinated and control macaques, despite a three logs reduction at mucosal sites of simian immunodeficiency virus (SIV) RNA in the vaccinated group. Even though a normal CD4+ T cell number is not reconstituted at mucosal sites in either group, vaccination appeared to confer a better preservation of the CD4+ CCR5+ T cells that replenish these sites. Analysis of rectal tissues RNA following challenge exposure demonstrated a decreased expression in vaccinated macaques of transforming growth factor-beta, cytotoxic T lymphocyte antigen-4, FoxP3, and indoleamine 2,3-dioxygenase, an immune suppressive enzyme expressed by dendritic cells that converts tryptophan to kynurenine and limits T-cell responses. Accordingly, the ratio of kynurenine and tryptophan in the plasma was significantly reduced in the vaccinated animals respect to the controls. Thus, preexisting adaptive immune responses induced by these vaccine modalities, although they do not protect from CD4+ T-cell depletion, nevertheless, they contain SIV(mac251) replication and delay expression of markers of T-cell activation and/or suppression at mucosal sites.


Asunto(s)
Apoptosis/inmunología , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD4-Positivos/patología , Síndrome de Inmunodeficiencia Adquirida del Simio/inmunología , Virus de la Inmunodeficiencia de los Simios/inmunología , Vacunas Virales/inmunología , Animales , Inmunidad Mucosa/inmunología , Macaca mulatta , Síndrome de Inmunodeficiencia Adquirida del Simio/genética , Síndrome de Inmunodeficiencia Adquirida del Simio/metabolismo , Síndrome de Inmunodeficiencia Adquirida del Simio/virología , Virus de la Inmunodeficiencia de los Simios/genética , Virus de la Inmunodeficiencia de los Simios/metabolismo , Vacunas de ADN/genética , Vacunas de ADN/inmunología , Vacunas de ADN/metabolismo
20.
J Med Virol ; 78(5): 551-60, 2006 May.
Artículo en Inglés | MEDLINE | ID: mdl-16555286

RESUMEN

Hepatitis B virus (HBV)-associated nephritis has been reported worldwide. Immune complex deposition has been accepted as its pathogenesis, although the association between the presence of local HBV DNA and viral antigen and the development of nephritis remains controversial. To understand better the roles played by HBV protein expression in the kidney, the global gene expression profile was studied in the kidney tissue of a lineage of HBV transgenic mouse (#59). The mice expressed HBsAg in serum, and HBsAg and HBcAg in liver and kidney, but without virus replication. Full-length HBV genome (adr subtype, C genotype) isolated from a chronic HBV carrier was used to establish the transgenic mice #59. Similarly manipulated mice that did not express HBV viral antigens served as controls. Southern blotting, hybridization with HBV probe, and immuno-histochemical staining were used to study HBV gene expression. mRNA extracted from the kidney tissue was analyzed using Affymetrix microarrays. HBsAg and HBcAg were located mainly in the cytoplasm of tubular epithelium. Altogether 520 genes were "up-regulated" more than twofold and 76 genes "down-regulated" more than twofold in the kidney. The complement activation, blood coagulation, and acute-phase response genes were markedly "up-regulated". Compared to the controls, the level of serum C3 protein was decreased in #59 mice, while the level of C3 protein from kidney extract was increased. Results indicate that expression of HBsAg and HBcAg in tubular epithelial cells of the kidney per se can up-regulate complement-mediated inflammatory gene pathways, in addition to immune complex formation.


Asunto(s)
Glomerulonefritis Membranosa/etiología , Antígenos del Núcleo de la Hepatitis B/metabolismo , Antígenos de Superficie de la Hepatitis B/metabolismo , Virus de la Hepatitis B/metabolismo , Animales , Proteína C-Reactiva/genética , Complemento C3/genética , Citoplasma/metabolismo , Epitelio/metabolismo , Regulación de la Expresión Génica , Genoma Viral , Antígenos del Núcleo de la Hepatitis B/genética , Antígenos de Superficie de la Hepatitis B/sangre , Antígenos de Superficie de la Hepatitis B/genética , Virus de la Hepatitis B/genética , Inmunohistoquímica , Riñón/metabolismo , Túbulos Renales/metabolismo , Hígado/metabolismo , Ratones , Ratones Transgénicos , Análisis por Matrices de Proteínas , ARN Mensajero/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA